Key result
Following the approval of DOACs, overall use of oral anticoagulants in Italian patients with nonvalvular atrial fibrillation increased from 38% in 2010 to 45% in 2014.
Why the study?
Antithrombotic treatment patterns in patients with nonvalvular atrial fibrillation in Italy needed evaluation before and after direct oral anticoagulants were approved.
Does the approval of DOACs improve oral anticoagulant prescription rates in patients with nonvalvular atrial fibrillation?
Observational
Does the approval of DOACs improve oral anticoagulant prescription rates in patients with nonvalvular atrial fibrillation?
Absolute Event Rate: 45% vs 38%
The introduction of DOACs in Italy was associated with a modest increase in oral anticoagulant use for NVAF, though significant undertreatment remains.
No takes yet. Share an insight, caveat, or question.
OAC uptake rose modestly post-DOAC approval; leaves open effects on outcomes and barriers in eligible NVAF patients.
Esposti et al. (2019) conducted an observational in Nonvalvular atrial fibrillation (NVAF). Post-DOACs period (2014) vs. Pre-DOACs period (2010) was evaluated on Overall use of oral anticoagulant (OAC) therapy. Following the approval of DOACs, overall use of oral anticoagulants in Italian patients with nonvalvular atrial fibrillation increased from 38% in 2010 to 45% in 2014.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: